4-AMINOPYRIDINE IN MULTIPLE-SCLEROSIS

被引：1
|
作者：
POLMAN, CH
VANDIEMEN, HAM
VANDONGEN, MMMM
KOETSIER, JC
VANLOENEN, AC
VANWALBEEK, HK
机构：
[1] FREE UNIV AMSTERDAM HOSP,DEPT MED PHYS,AMSTERDAM,NETHERLANDS
[2] FREE UNIV AMSTERDAM HOSP,DEPT PHARM,AMSTERDAM,NETHERLANDS
[3] ONZE LIEVE VROUW HOSP,DEPT NEUROL,AMSTERDAM,NETHERLANDS
来源：
ANNALS OF NEUROLOGY | 1990年 / 28卷 / 04期
关键词：
D O I：
10.1002/ana.410280421
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：589 / 589
页数：1
相关论文
共 50 条
  • [1] 4-AMINOPYRIDINE IN MULTIPLE-SCLEROSIS - PROLONGED ADMINISTRATION
    STEFOSKI, D
    DAVIS, FA
    FITZSIMMONS, WE
    LUSKIN, SS
    RUSH, J
    PARKHURST, GW
    NEUROLOGY, 1991, 41 (09) : 1344 - 1348
  • [2] EFFECTS OF 4-AMINOPYRIDINE IN PATIENTS WITH MULTIPLE-SCLEROSIS
    JONES, RE
    HERON, JR
    FOSTER, DH
    SNELGAR, RS
    MASON, RJ
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1983, 60 (03) : 353 - 362
  • [3] 4-AMINOPYRIDINE IMPROVES CLINICAL SIGNS IN MULTIPLE-SCLEROSIS
    STEFOSKI, D
    DAVIS, FA
    FAUT, M
    SCHAUF, CL
    ANNALS OF NEUROLOGY, 1987, 21 (01) : 71 - 77
  • [4] 4-AMINOPYRIDINE IMPROVES CLINICAL SIGNS IN MULTIPLE-SCLEROSIS
    STEFOSKI, D
    DAVIS, FA
    TYSZKA, MF
    SCHAUF, CL
    ANNALS OF NEUROLOGY, 1985, 18 (01) : 131 - 131
  • [5] MECHANISM OF ACTION OF 4-AMINOPYRIDINE IN THE SYMPTOMATIC TREATMENT OF MULTIPLE-SCLEROSIS
    DAVIS, FA
    STEFOSKI, D
    QUANDT, FN
    ANNALS OF NEUROLOGY, 1995, 37 (05) : 684 - 684
  • [6] 4-AMINOPYRIDINE ADMINISTERED ORALLY IMPROVES CLINICAL SIGNS IN MULTIPLE-SCLEROSIS
    DAVIS, FA
    STEFOSKI, D
    BINDOKAS, J
    SCHAUF, CL
    ANNALS OF NEUROLOGY, 1986, 20 (01) : 152 - 152
  • [7] ORALLY-ADMINISTERED 4-AMINOPYRIDINE IMPROVES CLINICAL SIGNS IN MULTIPLE-SCLEROSIS
    DAVIS, FA
    STEFOSKI, D
    RUSH, J
    ANNALS OF NEUROLOGY, 1990, 27 (02) : 186 - 192
  • [8] 4-AMINOPYRIDINE INDUCES FUNCTIONAL IMPROVEMENT IN MULTIPLE-SCLEROSIS PATIENTS - A NEUROPHYSIOLOGICAL STUDY
    VANDIEMEN, HAM
    POLMAN, CH
    VANDONGEN, MMMM
    NAUTA, JJP
    STRIJERS, RLM
    VANLOENEN, AC
    BERTELSMANN, FW
    KOETSIER, JC
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1993, 116 (02) : 220 - 226
  • [9] Neuroprotective effects of 4-aminopyridine in multiple sclerosis
    Koska, V.
    Dietrich, M.
    Hecker, C.
    Goettle, P.
    Hilla, A.
    Heskamp, A.
    Lepka, K.
    Issberner, A.
    Baksmeier, C.
    Steckel, J.
    Balk, L.
    Knier, B.
    Korn, T.
    Havla, J.
    Martinez-Lapiscina, E. H.
    Sola, N.
    Manogaran, P.
    Olbert, E. D.
    Schippling, S.
    Cruz-Herranz, A.
    Yiu, H.
    Button, J.
    Caldito, N. Gonzalez
    von Gall, C.
    Mausberg, A. K.
    Stettner, M.
    Zimmermann, H.
    Paul, F.
    Brandt, A. U.
    Kuery, P.
    Goebels, N.
    Aktas, O.
    Berndt, C.
    Saidha, S.
    Green, A. J.
    Calabresi, P. A.
    Fischer, D.
    Hartung, H. -P.
    Albrecht, P.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 308 - 310
  • [10] 4-AMINOPYRIDINE IN PATIENTS WITH MULTIPLE-SCLEROSIS - DOSAGE AND SERUM LEVEL RELATED TO EFFICACY AND SAFETY
    VANDIEMEN, HAM
    POLMAN, CH
    KOETSIER, JC
    VANLOENEN, AC
    NAUTA, JJP
    BERTELSMANN, FW
    CLINICAL NEUROPHARMACOLOGY, 1993, 16 (03) : 195 - 204
12345